Trilipix Uses
Links shared publicly online about this topic
FDA panel to weigh revoking key use of Trilipix - USATODAY.com
yourlife.usatoday.com — “A panel of advisers to the Food and Drug Administration will consider this week whether to revoke a key indication from Abbott's blockbuster cholesterol drug Trilipix.” View full resource at yourlife.usatoday.com
Most Recently Shared on May 17, 2011 at 5:07 pm By:
FDA panel to weigh revoking key use of Trilipix http://usat.ly/lV7WeK
Companies ask FDA to approve Crestor-Trilipix combo pill
theheart.org — “If the agency agrees, the companies will market the new drug as Certriad.” View full resource at theheart.org
Most Recently Shared on June 8, 2009 at 8:59 pm By:
heartwire: AstraZeneca, Abbott ask the FDA to approve Crestor-Trilipix combo pill http://bit.ly/qSacl
Comments of using Trilipix, Klonopin Rapidly Disintegrating, Tenex, Nuvigil, Strattera (study 6197294) - eHealthMe.com
ehealthme.com — “After increasing to Stratterra 100mg a few weeks ago, I have developed a tremor in my right hand. I'm also taking Nuvigil, so I wonder if that's too much? Is this permanent or just temporary? I'm finding it difficult to do things requiring fine motor skills in my right hand.” View full resource at ehealthme.com
Most Recently Shared on March 26, 2012 at 3:15 pm By:
After increasing to Stratterra 100mg a few weeks ago, I have developed a tremor in my right hand. I'm also ta http://t.co/BU0S26Na
Abbott And AstraZeneca Extend Relationship To Include Co-promotion Of TRILIPIX(R) (fenofibric Acid)
medicalnewstoday.com — “Abbott and astrazeneca announced today that they have entered into an agreement for astrazeneca to co-promote abbott's trilipix® (fenofibric acid), a medication for use alone or in combinatio” View full resource at medicalnewstoday.com
Most Recently Shared on June 10, 2009 at 11:45 pm By:
MedicalNewsToday: Abbott And AstraZeneca Extend Relationship To Include: http://tinyurl.com/lzkkyz Full http://tinyurl.com/llxvg9
FDA panel to weigh revoking key use of Abbott drug
health.yahoo.net — “A panel of advisers to the Food and Drug Administration will consider this week whether to revoke a key indication from Abbott's blockbuster cholesterol drug Trilipix.” View full resource at health.yahoo.net
Most Recently Shared on May 17, 2011 at 2:52 pm By:
Jane Anderson Healthy Eating Advisor
FDA panel to weigh revoking key use of Abbott drug http://bit.ly/mCfgFp
Use of fibrates to lower cholesterol growing despite mounting evidence they don't work - latimes.com
latimes.com — “The use of fibrates and fenofibrates to reduce cholesterol levels has grown sharply in the United States over the past decade, despite mounting evidence that the drugs provide little benefit, researchers reported Tuesday. Moreover, physicians are increasingly prescribing brand-name versions of the drugs, such as TriCor and Trilipix, despite the fact that published evidence so far shows a benefit only for generic forms of the drugs, such as gemfibrozil, researchers reported in the Journal of the ” View full resource at latimes.com
Most Recently Shared on March 23, 2011 at 1:03 am By:
LA Times Health News Health News
Use of fibrates to lower cholesterol growing despite mounting evidence they don't work http://lat.ms/fRpPk0
FDA panel to weigh revoking key use of Abbott drug
medicalxpress.com — “(AP) -- A panel of advisers to the Food and Drug Administration will consider this week whether to revoke a key indication from Abbott's blockbuster cholesterol drug Trilipix.” View full resource at medicalxpress.com
Most Recently Shared on May 17, 2011 at 5:15 pm By:
PhysOrg Health News Health News
FDA panel to weigh revoking key use of Abbott drug http://tw.medicalxpress.com/224856838
Fenofibrate Use Soars Despite Lack of Benefit (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- Prescriptions for fenofibrate (TriCor) and fenofibric acid (Trilipix) tripled from 2002 to 2009 -- even as clinical studies failed to confirm that they reduce cardiovascular events in diabetic patients, researchers said.” View full resource at qualitypointtech.net
Most Recently Shared on March 22, 2011 at 9:00 pm By:
Fenofibrate Use Soars Despite Lack of Benefit (CME/CE): (MedPage Today) -- Prescriptions for fenofibrate (TriCor) ... http://bit.ly/iaruxW
UPDATE 1-Adding Abbott drug to statin gets US FDA scrutiny | Reuters
reuters.com — “* FDA weighs revoking approval of Trilipix added to statin * Panel to provide recommendation on Thursday * Abbott says current label appropriate (Adds company comment) By Lisa Richwine WASHINGTON,” View full resource at reuters.com
Most Recently Shared on May 17, 2011 at 12:39 pm By:
RT @ReutersLisaRx #FDA to ask panel if Abbott's Trilipix should lose approval for combo use with statin http://t.co/ACG1NwP $ABT #Pharma
Abbott’s Ticking Time Bomb - Matthew Herper - The Medicine Show - Forbes
blogs.forbes.com — “On Thursday, Abbott Laboratories' heart drugs Tricor and TriLipix will face an FDA advisory panel which will examine how the medicines should be used given the lack of evidence for them. Although this controversy has flown under the radar compared to the one that hit Merck's Zetia a few years [...]” View full resource at blogs.forbes.com
Most Recently Shared on May 17, 2011 at 2:45 pm By:
Drugs and Devices OW OW Health
Abbott's Ticking Time Bomb: Controversy is brewing on Abbott's triglyceride lowering drug. http://onforb.es/lsZomE #drug
FDA Panel to Vote on Revoking Approval for Fenofibrate - QualityPoint Technologies
qualitypointtech.net — “WASHINGTON (MedPage Today) -- The FDA will ask a panel of cardiovascular experts whether it should revoke approval for Abbott's fenofibric acid (Trilipix) in light of findings from the ACCORD-Lipid trial that called into question the efficacy of using the heart drug as an add-on to statin therapy.” View full resource at qualitypointtech.net
Most Recently Shared on May 17, 2011 at 9:45 pm By:
FDA Panel to Vote on Revoking Approval for Fenofibrate: WASHINGTON (MedPage Today) -- The FDA will ask a panel of ... http://bit.ly/jEcRCD
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Maureen Linke
USA TODAY Your Life, including news on health, fitness, food, parenting, family, pets, aging, sex, relationships, self-improvement and body image (web producer)
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
eHealthMe.com
eHealthMe provides health professionals and patients personalized tools to study millions of drug reports from FDA and community in real time.
Advertisement
